Swiss regulations for controlling clinical trials

Area of Science:

• Regulatory Affairs
• Clinical Trials
• Drug Development

Background:

• Switzerland implemented new regulations for drug trials in 1995.
• These regulations align with international standards and introduced Good Clinical Practice (GCP).
• Existing federal and cantonal laws cover specific areas like immunobiological products and medical devices.

Purpose of the Study:

• To provide a comprehensive review of Swiss regulations for clinical trials.
• To examine regulations for therapeutic compound trials.
• To assess the compatibility of Swiss procedures with international standards.

Main Methods:

• Review of Swiss federal and cantonal regulations.
• Analysis of the 'Intercantonal Regulations Controlling Drugs used in Clinical Trials'.
• Comparison with international clinical trial guidelines and procedures.

Main Results:

• Switzerland's 1995 regulations standardize drug trial oversight.
• Good Clinical Practice (GCP) is now a key component of Swiss trial regulations.
• Cantonal regulations supplement central laws to cover all trial aspects.

Conclusions:

• Swiss regulations for drug trials are comprehensive and internationally aligned.
• The regulations ensure consistent oversight for therapeutic compound trials.
• Switzerland's framework supports compatible international clinical trial procedures.